EP4333979A4 - METHODS FOR TITRATION OF THE DOSE OF PSYCHEDELICS - Google Patents

METHODS FOR TITRATION OF THE DOSE OF PSYCHEDELICS

Info

Publication number: EP4333979A4
Authority: EP; European Patent Office
Prior art keywords: psychedelics; titration; dose; methods
Prior art date: 2021-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP22799340.9A

Other languages

German (de)

French (fr)

Other versions

EP4333979A1 (en

Inventor

Robert Barrow

Daniel R. Karlin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mind Medicine Inc

Original Assignee

Mind Medicine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-05-03

Filing date

2022-05-01

Publication date

2025-01-15

2022-05-01 Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc

2024-03-13 Publication of EP4333979A1 publication Critical patent/EP4333979A1/en

2025-01-15 Publication of EP4333979A4 publication Critical patent/EP4333979A4/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Dental Preparations (AREA)
Measurement Of Radiation (AREA)

EP22799340.9A 2021-05-03 2022-05-01 METHODS FOR TITRATION OF THE DOSE OF PSYCHEDELICS Pending EP4333979A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202163183579P	2021-05-03	2021-05-03
PCT/US2022/027179 WO2022235529A1 (en)	2021-05-03	2022-05-01	Method of titrating dose of psychedelics

Publications (2)

Publication Number	Publication Date
EP4333979A1 EP4333979A1 (en)	2024-03-13
EP4333979A4 true EP4333979A4 (en)	2025-01-15

Family

ID=83932279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22799340.9A Pending EP4333979A4 (en)	2021-05-03	2022-05-01	METHODS FOR TITRATION OF THE DOSE OF PSYCHEDELICS

Country Status (7)

Country	Link
EP (1)	EP4333979A4 (en)
JP (1)	JP2024517194A (en)
AU (2)	AU2022268891A1 (en)
CA (1)	CA3216939A1 (en)
IL (1)	IL308068A (en)
TW (1)	TW202245767A (en)
WO (1)	WO2022235529A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2021268204A1 (en)	2020-05-08	2022-12-08	Psilera Inc.	Novel compositions of matter and pharmaceutical compositions
CN117355302A (en)	2021-04-30	2024-01-05	思维医学股份有限公司	LSD salt crystal form
IL308816A (en)	2021-05-25	2024-01-01	Atai Therapeutics Inc	SALTS AND CRYSTALLINE FORMS OF N,N-DIMETHYLTRYPTAMINE
MX2023014620A (en)	2021-06-09	2024-01-30	Atai Therapeutics Inc	Novel prodrugs and conjugates of dimethyltryptamine.
JP2024529727A (en)	2021-08-19	2024-08-08	マインドメディシン，インコーポレイテッド	Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
WO2023019369A1 (en)	2021-08-20	2023-02-23	Pharmala Biotech Inc.	Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
JP2024545787A (en)	2021-12-30	2024-12-11	アタイセラピューティクス，インコーポレイテッド	Dimethyltryptamine analogues as nitric oxide delivery agents.
WO2023168023A1 (en)	2022-03-04	2023-09-07	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170157343A1 (en) *	2014-06-30	2017-06-08	Syqe Medical Ltd.	Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (en) *	2019-01-30	2020-08-06	Diamond Therapeutics Inc.	Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
WO2020169850A1 (en) *	2019-02-22	2020-08-27	Gh Research Limited	5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA50786A (en) *	2017-10-26	2022-04-27	Blumentech S L	COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
WO2021003467A1 (en) *	2019-07-04	2021-01-07	Sw Holdings, Inc.	Metered dosing compositions and methods of use of psychedelic compounds

2022
- 2022-05-01 EP EP22799340.9A patent/EP4333979A4/en active Pending
- 2022-05-01 CA CA3216939A patent/CA3216939A1/en active Pending
- 2022-05-01 JP JP2023566881A patent/JP2024517194A/en active Pending
- 2022-05-01 AU AU2022268891A patent/AU2022268891A1/en not_active Abandoned
- 2022-05-01 WO PCT/US2022/027179 patent/WO2022235529A1/en not_active Ceased
- 2022-05-01 IL IL308068A patent/IL308068A/en unknown
- 2022-05-03 TW TW111116665A patent/TW202245767A/en unknown
2025
- 2025-08-12 AU AU2025217270A patent/AU2025217270A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170157343A1 (en) *	2014-06-30	2017-06-08	Syqe Medical Ltd.	Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (en) *	2019-01-30	2020-08-06	Diamond Therapeutics Inc.	Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
WO2020169850A1 (en) *	2019-02-22	2020-08-27	Gh Research Limited	5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "How to Microdose: A Step by Step Guide - Microdosing information, research, community, coaching and more.", 30 April 2021 (2021-04-30), pages 1 - 9, XP093230199, Retrieved from the Internet <URL:https://web.archive.org/web/20210430131601/https://microdosinginstitute.com/how-to/how-to-microdose/> *
KUYPERS KIM P.C.: "The therapeutic potential of microdosing psychedelics in depression", vol. 10, 27 August 2020 (2020-08-27), XP093229382, ISSN: 2045-1253, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2045125320950567> DOI: 10.1177/2045125320950567 *
See also references of WO2022235529A1 *

Also Published As

Publication number	Publication date
AU2022268891A1 (en)	2023-11-09
EP4333979A1 (en)	2024-03-13
TW202245767A (en)	2022-12-01
AU2025217270A1 (en)	2025-08-28
JP2024517194A (en)	2024-04-19
WO2022235529A1 (en)	2022-11-10
CA3216939A1 (en)	2022-11-10
IL308068A (en)	2023-12-01

Legal Events

Date	Code	Title	Description
2022-11-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-12-05	TPAA	Information related to observations by third parties modified	Free format text: ORIGINAL CODE: EPIDOSCTIPA
2023-12-05	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2024-02-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2024-02-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-03-13	17P	Request for examination filed	Effective date: 20231130
2024-03-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-08-07	DAV	Request for validation of the european patent (deleted)
2024-08-07	DAX	Request for extension of the european patent (deleted)
2024-12-10	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0025000000 Ipc: A61K0031137000
2025-01-15	A4	Supplementary search report drawn up and despatched	Effective date: 20241216
2025-01-15	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/00 20060101ALI20241210BHEP Ipc: A61K 31/675 20060101ALI20241210BHEP Ipc: A61K 31/48 20060101ALI20241210BHEP Ipc: A61K 31/4045 20060101ALI20241210BHEP Ipc: A61K 31/137 20060101AFI20241210BHEP
2025-09-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-10-22	17Q	First examination report despatched	Effective date: 20250919
2026-03-11	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: DEFINIUM THERAPEUTICS US, INC.

Publication	Publication Date	Title
EP4333979A4 (en)	2025-01-15	METHODS FOR TITRATION OF THE DOSE OF PSYCHEDELICS
EP4069212A4 (en)	2024-03-06	INHIBITORS OF HIF-2ALPHA
EP3634402C0 (en)	2026-01-21	METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS
EP4289996C0 (en)	2026-02-11	METHOD FOR INDICATION OF NUCLEAN ACIDS
EP4065114C0 (en)	2025-11-05	METHOD FOR THE PREPARATION OF RELUTRIGINE/PRAX-562
EP3277276A4 (en)	2019-02-06	METHOD FOR THE ADMINISTRATION OF GLUTAMINEASE INHIBITORS
EP3538494A4 (en)	2020-07-15	METHOD FOR THE ELECTROCHEMICAL TREATMENT OF WATER
EP3540433A4 (en)	2020-08-19	SYSTEM FOR ESTIMATING THE CONCENTRATION OF SOIL INJECTION AGENTS
EP3893883A4 (en)	2022-09-07	METHODS OF TREATMENT OF DEPRESSION
EP3941921A4 (en)	2023-05-03	THERAPEUTIC METHODS OF TREATMENT OF HEPATITIS B
EP3897582C0 (en)	2024-09-11	PROCESS FOR SPRAY DRYING OF SEMAGLUTIDE
EP3583521A4 (en)	2020-08-12	PROCEDURE FOR EXECUTION OF PARTIAL SHARE ORDERS
EP4227290C0 (en)	2024-05-22	PROCEDURE FOR REUSE OF DMTM
EP3578161A4 (en)	2020-12-23	PROCESS FOR IMPROVING THE STORAGE STABILITY OF COSMETICS
EP3833752A4 (en)	2022-06-01	METHODS OF TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE II
EP3426632A4 (en)	2020-02-26	INHIBITORS OF CREB-CBP INTERACTION FOR TREATING LEUKEMIA
EP4395815A4 (en)	2025-07-30	Methods for improving the stability of immune checkpoint inhibitors
EP3826664A4 (en)	2022-10-26	METHODS OF TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE I
EP3756133A4 (en)	2021-11-17	PROCEDURE FOR THE AUTHENTICATION OF ITEMS
EP3786904C0 (en)	2025-02-26	PROCEDURE FOR THE TELEMATICAL PROVISION OF VEHICLE COMPONENT ASSESSMENT
EP3816298A4 (en)	2022-03-16	PROCEDURE FOR DETERMINING THE CYTOTOXICITY OF GAS
EP3761207C0 (en)	2023-08-30	PROCEDURE FOR COMMITTING CONTENT OF BLOCKCHAIN OPERATIONS
EP3746102C0 (en)	2025-11-05	METHOD FOR THE ISSUANCE OF CYTISIN
DE112019002959A5 (en)	2021-04-08	Method for the detection of beacons
EP3692174A4 (en)	2021-06-23	METHOD FOR TREATMENT OF LYMPHOMAS